Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Immatics N.V. Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.	United States of America	IMTX
Immix Biopharma, Inc. Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.	United States of America	IMMX
IMMUCELL CORP /DE/ Develops biotech health products for disease prevention in dairy and beef cattle.	United States of America	ICCC
Immuneering Corp Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.	United States of America	IMRX
ImmuneOncia Therapeutics, Inc. A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.	South Korea	424870
ImmunityBio, Inc. Develops immunotherapies activating the immune system to fight cancer and infectious diseases.	United States of America	IBRX
Immuno-Biological Laboratories Co., Ltd. Develops and supplies immunological reagents and diagnostics for research and drug discovery.	Japan	4570
Immunocore Holdings plc Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.	United States of America	IMCR
Immunome Inc. Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.	United States of America	IMNM
Immunovant, Inc. Developing novel, FcRn-targeted therapies for people with autoimmune diseases.	United States of America	IMVT